eScreen, Inc. and Alere Announce Acquisition

Overland Park, KS – February 29, 2012

Alere

eScreen and Alere, Inc. (NYSE: ALR) today announced that they have entered into a binding agreement under which Alere will acquire eScreen for a base purchase price of $270 million cash subject to a customary working capital adjustment and follow-on contingent consideration of up to an additional $70 million. The acquisition is expected to close within the next 45 days, but remains subject to customary closing conditions.

Alere, Inc. is a global leader in enabling individuals to take charge of their health through the merger of rapid diagnostics and health management. eScreen deploys a class-leading automated platform and FDA-cleared reader for the collection, provision, management and reporting of regulated and non-regulated urine drug screens. The company also offers a growing portfolio of employee-related health testing products and services, and had revenues of approximately $120 million in 2011.

Commenting on the agreement, Ron Zwanziger, CEO of Alere said, “With the acquisition of eScreen, we not only further our capabilities in the global toxicology market, but also strongly position Alere to deliver a wide-range of diagnostics to US and multi-national employers. The eScreen platform is foundational in our approach, as employers are increasingly shouldering the burden for the care of their workforce and are more directly dictating their health testing needs.”

In a related statement, Dr. Murray Lappe, Founder and Chairman of the Board of eScreen, said, “We believe that this combination will greatly enhance our ability to realize our founding vision of improving the delivery, efficiency and effectiveness of employee health. Both companies share a history of success in diagnostics and toxicology, and together we are poised for growth through our plans to deploy new products on the eScreen platform.”

eScreen used Evercore Partners as its financial advisor, and Covington & Burling LLP and Miller Nash LLP as its legal counsel.

About eScreen, Inc.

eScreen is a technology-driven services firm that specializes in drug-screening and employee health products and services. The company set itself apart early on when it created the only FDA-cleared instant drug test. That revolutionary development, the eReader®, is eScreen's exclusive, instrumented, 15-minute, negative urine drug-screening device. The eReader set the standard for the entire drug-testing industry. It also set the stage for the wide range of innovative products and services the company offers today. These include eScreen123™, the first paperless chain-of-custody form; and MyeScreen™, the industry-leading web-based result reporting and program management software.

The company's newest product, Health-eScreen™, is an electronic application to schedule, process and deliver reports on medical services and physical exams via the eScreen platform.

Founded in 1998 by Dr. Murray Lappe and located in Overland Park, Kan., eScreen is the largest Third-Party Administrator (TPA) of Drug Free Workplace programs in the United States. In that role, the company processes millions of corporate-data transactions each year for employers of all sizes. For details on eScreen's integrated, electronic drug screening, health services and other innovative workplace solutions, please visit www.escreen.com.

Media Contact for eScreen, Inc:

Johnna Guinty
913-327-5915 (x2217)
jguinty@escreen.com